Native Study of the Behaviour of Magnetite Nanoparticles for Hyperthermia Treatment during the Initial Moments of Intravenous Administration.
biological fluids
biological identity
flow field flow fractionation (FFF)-multidetection
hyperthermia treatment
intravenous administration
magnetic nanoparticles
native characterization
protein corona
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
15 Dec 2022
15 Dec 2022
Historique:
received:
18
11
2022
revised:
06
12
2022
accepted:
13
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Magnetic nanoparticles (MNPs) present outstanding properties making them suitable as therapeutic agents for hyperthermia treatments. Since the main safety concerns of MNPs are represented by their inherent instability in a biological medium, strategies to both achieve long-term stability and monitor hazardous MNP degradation are needed. We combined a dynamic approach relying on flow field flow fractionation (FFF)-multidetection with conventional techniques to explore frame-by-frame changes of MNPs injected in simulated biological medium, hypothesize the interaction mechanism they are subject to when surrounded by a saline, protein-rich environment, and understand their behaviour at the most critical point of intravenous administration. In the first moments of MNPs administration in the patient, MNPs change their surrounding from a favorable to an unfavorable medium, i.e., a complex biological fluid such as blood; the particles evolve from a synthetic identity to a biological identity, a transition that needs to be carefully monitored. The dynamic approach presented herein represents an optimal alternative to conventional batch techniques that can monitor only size, shape, surface charge, and aggregation phenomena as an averaged information, given that they cannot resolve different populations present in the sample and cannot give accurate information about the evolution or temporary instability of MNPs. The designed FFF method equipped with a multidetection system enabled the separation of the particle populations providing selective information on their morphological evolution and on nanoparticle-proteins interaction in the very first steps of infusion. Results showed that in a dynamic biological setting and following interaction with serum albumin, PP-MNPs retain their colloidal properties, supporting their safety profile for intravenous administration.
Identifiants
pubmed: 36559302
pii: pharmaceutics14122810
doi: 10.3390/pharmaceutics14122810
pmc: PMC9782478
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Union
ID : 760928
Références
Molecules. 2022 Aug 27;27(17):
pubmed: 36080273
J Chromatogr A. 2014 Oct 30;1372C:196-203
pubmed: 25468501
R Soc Open Sci. 2018 Jan 31;5(1):171113
pubmed: 29410826
Langmuir. 2013 Dec 3;29(48):14984-96
pubmed: 24215427
Sci Rep. 2019 Jul 24;9(1):10765
pubmed: 31341232
PLoS One. 2010 Jun 03;5(6):e10949
pubmed: 20532175
Anal Chem. 2015 Aug 18;87(16):8441-7
pubmed: 26222150
Methods Mol Biol. 2017;1570:47-71
pubmed: 28238129
Adv Colloid Interface Sci. 2011 Aug 10;166(1-2):8-23
pubmed: 21601820
Molecules. 2022 Aug 26;27(17):
pubmed: 36080254
Int J Nanomedicine. 2013;8:747-65
pubmed: 23459088
RSC Adv. 2018 Jan 3;8(2):904-913
pubmed: 35538965
ACS Nano. 2018 Jul 24;12(7):7292-7300
pubmed: 29953205
J Control Release. 2022 May;345:832-850
pubmed: 35367478
Adv Drug Deliv Rev. 2022 Jul;186:114356
pubmed: 35595022
Nanoscale. 2018 Jul 13;10(27):12871-12934
pubmed: 29926865
Adv Drug Deliv Rev. 2009 Jun 21;61(6):467-77
pubmed: 19389434
Anal Bioanal Chem. 2018 Aug;410(20):4867-4873
pubmed: 29808297
J Chromatogr A. 2021 Jan 11;1636:461739
pubmed: 33316566
J Pharm Biomed Anal. 2014 Jan;87:53-61
pubmed: 24012480
Anal Chim Acta. 2022 Feb 8;1193:339396
pubmed: 35058014
Anal Bioanal Chem. 2011 Jan;399(1):197-203
pubmed: 20852849
J Control Release. 2012 Jul 20;161(2):505-22
pubmed: 22353619
J Exp Clin Cancer Res. 2011 Sep 26;30:87
pubmed: 21943236
Anal Bioanal Chem. 2018 Aug;410(21):5245-5253
pubmed: 29947896
Spectrochim Acta A Mol Biomol Spectrosc. 2015 Jan 25;135:536-9
pubmed: 25123943
Expert Rev Clin Pharmacol. 2012 Mar;5(2):173-86
pubmed: 22390560
Bioorg Chem. 2018 Feb;76:501-509
pubmed: 29310081
Materials (Basel). 2021 Jan 06;14(2):
pubmed: 33419055
J Chromatogr A. 2021 Feb 8;1638:461861
pubmed: 33472105
Colloids Surf B Biointerfaces. 2021 Nov;207:112037
pubmed: 34416445
Antibiotics (Basel). 2022 Mar 08;11(3):
pubmed: 35326821
J Control Release. 2007 May 14;119(1):52-8
pubmed: 17350131
J Chromatogr A. 2014 Sep 5;1358:217-24
pubmed: 25064532
J Mater Chem. 2008;18(11):1204-1208
pubmed: 19122852
J Mater Chem B. 2020 Jul 22;8(28):5973-5991
pubmed: 32597454
Chem Commun (Camb). 2009 Sep 7;(33):5009-11
pubmed: 19668832
Biofizika. 2010 Jul-Aug;55(4):605-11
pubmed: 20968070
Artif Cells Nanomed Biotechnol. 2018 Sep;46(6):1146-1155
pubmed: 28789586
Mol Pharm. 2018 Sep 4;15(9):3823-3836
pubmed: 30024758
J Chromatogr A. 2006 Feb 3;1104(1-2):272-81
pubmed: 16360663
ACS Appl Mater Interfaces. 2022 Mar 23;14(11):13743-13757
pubmed: 35263991
J Chromatogr A. 2021 Jan 25;1637:461806
pubmed: 33360435
J Pharm Biomed Anal. 2015 Mar 15;106:92-9
pubmed: 25698553
Anal Bioanal Chem. 2022 Jul;414(18):5519-5527
pubmed: 35182166